ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and Bladder Cancer

October 20, 2020
Brielle Gregory, ASCO staff

The 2020 European Society for Medical Oncology (ESMO) Virtual Congress was held online from September 19 to September 21. In this podcast, Neeraj Agarwal, MD, discusses 3 clinical trials on genitourinary (GU) cancers presented at the meeting and what people with cancer should know about them.

  • Results from the phase III CheckMate 9ER clinical trial, which studied whether a combination of the angiogenesis inhibitor cabozantinib (Cometriq) with the immunotherapy drug nivolumab (Opdivo) improved the quality of life for people with advanced kidney cancer, as well as how long it stopped the cancer from growing. [2:35]

  • Findings from the phase III PROfound clinical trial, which examined whether treating advanced prostate cancer with the targeted therapy olaparib (Lynparza) helped specific patients with a biomarker live longer. [5:16]

  • Research from the phase III JAVELIN Bladder 100 clinical trial, which studied whether treating advanced bladder cancer with the immunotherapy drug avelumab (Bavencio) in people who had already received platinum-based chemotherapy helped them live longer. [11:18]

Dr. Agarwal is a professor of medicine and the director of the Genitourinary Oncology Program at the Huntsman Cancer Institute at the University of Utah in Salt Lake City, Utah. He is also a Cancer.Net Specialty Editor for Genitourinary Cancer. View Dr. Agarwal’s disclosure information.

Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts on Apple Podcasts or Google Play. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.

Cancer.Net podcasts are edited for length and content.

Share your thoughts on this blog post on Cancer.Net's Facebook and Twitter.